HCQ could also prevent β2-glycoprotein I complex from binding to phospholipid bilayers and cells and protect the annexin A5 anticoagulant shield from being destroyed by antiphospholipid antibodies, which was considered to decrease the risk of thrombosis in APS and SLE (69, 70). Here, ANXA5 is linked to systemic lupus erythematosus.